Goldin v. Smith & Nephew, Inc.
Filing
16
MEMORANDUM AND ORDER: granting 9 Motion to Dismiss. For the foregoing reasons, Defendants motion to dismiss is GRANTED without prejudice. Plaintiff is granted to leave to file an amended complaint within the next 60 days. The Clerk of Court is directed to close the motion at Dkt. No. 9. SO ORDERED.(Signed by Judge J. Paul Oetken on 4/24/2013) (ama)
UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK
--------------------------------------------------------------X
:
JANA GOLDIN,
:
Plaintiff, :
:
-against:
:
SMITH & NEPHEW, INC.,
:
Defendant. :
:
------------------------------------------------------------- X
12 Civ. 9217 (JPO)
MEMORANDUM AND
ORDER
J. PAUL OETKEN, District Judge:
This is a products liability case brought by Plaintiff Jana Goldin against Defendant Smith
& Nephew, Inc. with respect to the R3 Constrained Acetabular Liner. Defendant has filed a
motion to dismiss the Complaint. For the reasons that follow, Defendant’s motion is granted and
Plaintiff is granted leave to file an amended complaint within the next 60 days.
I.
Background 1
Following a diagnosis of loss of joint space, Plaintiff underwent right total hip
replacement in July 2009. Approximately four months later, Plaintiff developed right groin pain.
Testing revealed that she had developed a mental sensitivity. On May 4, 2010, Plaintiff
underwent revision and exchange of the metal components with metal and polyethylene
components. After this revision surgery, Plaintiff experienced three episodes of recurrent
instability, each consistent with anterior dislocation. As a result, her physician recommended
that she undergo revision total hip replacement with conversion to a constrained liner.
1
These facts are taken from the Complaint and assumed to be true for purposes of this opinion.
See Allaire Corp. v. Okumus, 433 F.3d 248, 249-50 (2d Cir. 2006).
1
On June 8, 2010, Plaintiff had revision surgery performed at New York University
Hospital for Joint Diseases, utilizing the Smith & Nephew 56mm R3 acetabular component with
screw fixation, 22mm inside diameter constrained polyethylene liner, and 22mm +4mm modular
femoral head. Smith & Nephew had marketed the R3 Constrained Liner for patients at high risk
of dislocation due to a history of dislocation, and the R3 Constrainer Liner was recommended to
Plaintiff by her surgeon, and accepted by Plaintiff, based on this representation. After the
prosthesis was fully implanted, Plaintiff’s surgeon placed Plaintiff’s hip through a full range of
motion and found the components to be secure with excellent stability. An x-ray taken the day
of the surgery showed the components to be in good position and alignment, as did x-rays taken
at a six-week follow-up visit. At that follow-up visit, Plaintiff was noted to be making good
progress toward regaining her range of motion, ambulation, and overall function. She was
advised to begin increasing her physical activities and was told that she could return to work on
July 26, 2010.
On August 12, 2010, Plaintiff was taking a shower when she experienced excruciating
pain in her right hip. She was taken by ambulance to the NYU Hospital for Joint Diseases,
where x-rays revealed that the right femoral head had become dislodged from the polyethylene
liner. The liner itself was not displaced, leading the surgeon to conclude that the problem was
with the constrained liner. Because of this failure of the constrained liner, Plaintiff was advised
to undergo another revision surgery. During that surgery, the surgeon checked the acetabular
component and found the screws to be secure and in the proper position. A liner with a 20
degree offset was chosen to enhance stability, trial reductions were performed to find
components with a good range of motion and stability, and a 40mm modular femoral head and
+8mm sleeve were selected and impacted into place. The femoral head was reduced onto the
2
acetabular component, and the implant checked and found to provide good stability and range of
motion. On August 13, 2010, Smith & Nephew issued a voluntary recall of R3 Constrained
Acetabular Liners, warning of the risk of intra-operative and post-operative dislocation.
Plaintiff filed suit against Smith & Nephew on November 28, 2012 in the Supreme Court
of the State of New York, County of Bronx. Her Complaint alleged causes of action for strict
products liability under manufacturing defect, design defect, and failure to warn theories of
liability, breach of implied warranty, breach of express warranty, negligence, and violations of
New York’s consumer protection statute. On December 18, 2010, Smith & Nephew filed a
notice of removal to this Court. On January 25, 2013, it filed a motion to dismiss.
II.
Standard of Review
To survive a motion to dismiss pursuant to Federal Rule 12(b)(6), a plaintiff must plead
sufficient factual allegations “to state a claim to relief that is plausible on its face.” Bell Atlantic
Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is facially plausible “when the plaintiff
pleads factual content that allows the court to draw the reasonable inference that the defendant is
liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). In other words,
the “[f]actual allegations must be enough to raise a right to relief above the speculative level.”
Twombly, 550 U.S. at 555. The Court must accept as true all well-pleaded factual allegations in
the complaint, and “draw [ ] all inferences in the plaintiff's favor.” Allaire Corp. v. Okumus, 433
F.3d 248, 249-50 (2d Cir. 2006) (internal quotations omitted). That said, “the tenet that a court
must accept as true all of the allegations contained in a complaint is inapplicable to legal
conclusions. Threadbare recitals of the elements of a cause of action, supported by mere
conclusory statements, do not suffice.” Iqbal, 556 U.S. at 678. In a recent summary of the
plausibility standard, the Second Circuit explained that:
3
[Twombly] stated that a complaint attacked by a Rule 12(b)(6)
motion to dismiss does not need detailed factual allegations, but
mere labels and conclusions or formulaic recitations of the
elements of a cause of action will not do; rather, the complaint’s
factual allegations must be enough to raise a right to relief above
the speculative level, i.e., enough to make the claim plausible.
Arista Records, LLC v. Doe 3, 604 F.3d 110, 120 (2d Cir. 2010) (quoting Twombly, 550 U.S. at
555, 570) (quotation marks and internal citations omitted). The Circuit clarified that this rule
“does not impose a probability requirement at the pleading stage; it simply calls for enough facts
to raise a reasonable expectation that discovery will reveal evidence of illegality.” Id. (citing
Twombly, 550 U.S. at 556) (quotation marks omitted).
III.
Discussion
A.
Strict Liability
1.
Manufacturing Defect
“A manufacturing defect claim is premised on the relevant product being defective
because it was not manufactured as designed.” Reed v. Pfizer, Inc., 839 F. Supp. 2d 571, 577
(E.D.N.Y. 2012) (citations omitted); see also Derienzo v. Trek Bicycle Corp., 376 F. Supp. 2d
537, 560 (S.D.N.Y. 2005) (“The crux of a . . . manufacturing defect claim is the product’s failure
to perform as expected due to an error in the manufacturing process that resulted in a defect.”).
Under New York law, “[t]o plead and prove a manufacturing flaw under either negligence or
strict liability, the plaintiff must show that a specific product unit was defective as a result of
‘some mishap in the manufacturing process itself, improper workmanship, or because defective
materials were used in construction,’ and that the defect was the cause of plaintiff’s injury.”
Colon ex rel. Molina v. BIC USA, Inc., 199 F. Supp. 2d 53, 85 (S.D.N.Y. 2001) (quotation marks
and citation omitted). Thus, a manufacturing defect claim is properly dismissed if a plaintiff has
4
not alleged that “the particular [product] administered to her had a defect as compared to other
samples of that [product].” Reed, 839 F. Supp. 2d at 577 (quotation marks and citation omitted);
see also Pinello v. Andreas Stihl Ag & Co. KG, No. 8 Civ. 452, 2011 WL 1302223, at *16
(N.D.N.Y. Mar. 31, 2011) (“Plaintiff fails to plead which part of the cutoff was defective, or in
what way some particular defect caused Plaintiff’s injury, as a result of a mishap in the
manufacturing process, improper workmanship, or because of defective materials used in
construction.”).
Plaintiff has failed to allege any facts regarding the manufacturing process. The
Complaint says nothing about a mishap in the manufacturing process, improper workmanship, or
use of defective materials. As a result, there is no reason at all to believe that the particular R3
Constrained Liner used in her surgery was defective as compared to other products manufactured
pursuant to the same design. See Am. Guarantee & Liab. Ins. Co. v. Cirrus Design Corp., No.
09 Civ. 8357, 2010 WL 5480775, at *3 (S.D.N.Y. Dec. 30, 2010) (“Plaintiffs have not only
failed to specify the defective component but have also failed to adequately allege any deviations
from the manufacturing process, improper workmanship, or defective materials.”); Lewis v.
Abbott Laboratories, No. 08 Civ. 7480, 2009 WL 2231701, at *6 (S.D.N.Y. July 24, 2009) (“In
the present case, plaintiff does not assert a manufacturing defect claim. She does not allege that
the particular Depakote administered to her had a defect as compared to other Depakote.”);
Barrett v. Black & Decker (U.S.) Inc., No. 06 Civ. 1970, 2008 WL 5170200, at *11 (S.D.N.Y.
Dec. 9, 2008) (“Plaintiff fails to plead which part of the saw was defective, or in what way some
particular defect caused plaintiff’s injury.”).
Plaintiff argues that her Complaint nonetheless should survive because she has alleged
facts suggesting that the product did not perform as intended and by excluding all other causes
5
for the product’s failure. New York law does recognize the validity of such a circumstantial case
for products liability, particularly where, as here, the plaintiff no longer remains in possession of
the disputed product. See Speller ex rel. Miller v. Sears, Roebuck & Co., 100 N.Y.2d 38, 41
(2003) (“In order to proceed in the absence of evidence identifying a specific flaw, a plaintiff
must prove that the product did not perform as intended and exclude all other causes for the
product’s failure that are not attributable to defendants.”); see also Riegel v. Medtronic, Inc., 451
F.3d 104, 125 (2d Cir. 2006) aff’d, 552 U.S. 312 (2008); Quinlan v. Stryker Corp., No. 09 Civ.
7284, 2010 WL 3291807, at *1 (S.D.N.Y. Aug. 12, 2010).
Here, however, Plaintiff has not adequately alleged facts in support of her claim that there
is no other possible cause for her product’s failure. Rather, she alleges only that several possible
causes have been excluded and that her surgeon concluded that “the problem was with the
constrained liner.” She does not allege that her surgeon viewed the problem with the constrained
liner as a manufacturing defect, that the only possible cause of her injury was such a defect in the
product, or, most importantly, that the circumstantial case supports the conclusion that this
otherwise adequately designed product must have suffered from a manufacturing defect of the
sort described above. 2 If Plaintiff is going to rely on the circumstantial theory of liability
described in New York case law, she must allege more facts to nudge her claim above the level
of speculation and into the realm of the plausible.
2.
Design Defect
“A design defect claim . . . is premised on a manufacturer’s failure to properly design a
product, which is then placed on the market despite posing inappropriate risks.” Reed, 839 F.
2
Plaintiff deploys this argument in the context of her manufacturing defect claim, but it might be
just as applicable to her design defect claim. It would nonetheless fail in that context too, at least
at this stage in the litigation and on the basis of this version of the Complaint, for similar reasons.
6
Supp. 2d at 577 (citations omitted). “Generally, a plaintiff seeking to impose strict liability for a
design defect must show that: (1) the product as designed posed a substantial likelihood of harm;
(2) it was feasible to design the product in a safer manner; and (3) the defective design was a
substantial factor in causing the plaintiff’s injury.” Pinello, 2011 WL 1302223, at *15 (citations
omitted). It is “well established in New York state courts that in order to establish a prima facie
case based on a design defect, plaintiff must offer evidence that it was feasible to design the
product in a safer manner and that the proposed design would have prevented some of plaintiff’s
injuries.” Ferracane v. United States, No. 02 Civ. 1037, 2007 WL 316570, at *5 (E.D.N.Y. Jan.
30, 2007) (quotation marks and citation omitted); see also Reed, 839 F. Supp. 2d at 578
(“Plaintiffs’ design defect claim also fails for an additional reason. Plaintiffs do not plead facts
alleging the existence of a feasible alternative design that would make the product safer, as is
required to establish a design defect, under either New York or West Virginia law.” (citations
omitted)).
Plaintiff has not alleged any facts to demonstrate that the product as designed posed a
substantial likelihood of harm or that it was feasible to design the product in a safer manner that
would have prevented Plaintiff’s injuries. Plaintiff states that the product poses a risk of harm
because of its propensity to dislocate, but does not identify any particular problem in the design
of the product or identify an alternative design. The bare fact of the voluntary recall does not
suffice to prove a design defect. Plaintiff asks the Court to take judicial notice of the fact that
“most hip implants do not dislocate during revision surgery,” but that is not the proper question.
Rather, the question is whether a safer alternative design for this product existed—and, more
precisely, whether Plaintiff has alleged that fact in her Complaint. In the absence of factual
allegations identifying an existing design defect, this claim cannot succeed. See Am. Guarantee,
7
2010 WL 5480775, at *3 (S.D.N.Y. Dec. 30, 2010) (“In their Amended Complaint, Plaintiffs do
not specify a particular design defect, nor do they make any mention of a feasible alternative
design. Plaintiffs do not offer sufficiently detailed facts that would allow a reasonable person to
conclude that the product should not have been marketed in its present form.”); Lewis, 2009 WL
2231701, at *4 (“[P]laintiff’s allegations are conclusory. Further, plaintiff has not alleged that it
was feasible for Abbott Laboratories to design Depakote in a safer manner. Thus, plaintiff has
not met her burden to allege evidence that Depakote is not reasonably safe.” (citation omitted)).
3.
Failure to Warn
To prevail on a failure to warn claim, a plaintiff must prove that “(1) a manufacturer has a
duty to warn (2) against dangers resulting from foreseeable uses about which it knew or should
have known, and (3) that failure to do so was the proximate cause of the harm.” State Farm Fire
& Cas. Co. v. Nutone, Inc., 426 Fed. App’x 8, 10 (2d Cir. 2011) (citing Liriano v. Hobart Corp.,
92 N.Y.2d 232, 237 (1998)). To satisfy these elements, a plaintiff must “prove that the product
did not contain adequate warnings.” Mulhall v. Hannafin, 841 N.Y.S.2d 282, 285 (1st Dep’t
2007). Thus, “a failure to warn cause of action is appropriately dismissed if a plaintiff does not
plead facts indicating how the provided warnings were inadequate.” Reed, 839 F. Supp. 2d at
575 (citation omitted). “New York recognizes two circumstances in which a manufacturer has
no duty to warn of known of foreseeable dangers: first, where the dangers are obvious; and
second, where the user is fully aware of those dangers.” Pinello, 2011 WL 1302223, at *11
(citation omitted).
Plaintiff does not identify the allegedly defective warnings, nor does she allege facts in
support of her claim that these warnings were, in fact, defective. She does not identify the
promotional materials upon which she and her surgeon allegedly relied, nor does she explain
8
what warnings those materials contained and how those materials breached a legal obligation.
Standing alone, the bare fact that Plaintiff suffered an injury after using a product that had been
promoted for patients in her situation does not render the warnings inadequate. See Reed, 839 F.
Supp. 2d at 576-77 (“To cut to the chase, the fact . . . that Ms. Reed suffered from certain
conditions that were also identified risks of ingesting Lybrel is tragic, but cannot alone make
plausible a claim that defendants misrepresented or hid those risks in some way.”); Am.
Guarantee, 2010 WL 5480775, at *3 (“Plaintiffs have not pleaded sufficient facts to allow the
Court to make a reasonable inference that the lack of warning was a substantial factor in causing
the accident. As Plaintiffs have not adequately specified the danger that was not warned against,
they cannot state a plausible claim for failure to warn.”).
B.
Breach of Implied Warranty
An “implied warranty is breached where the product in question is not fit for the ordinary
purpose for which it is to be used.” Plemmons v. Steelcase Inc., No. 04 Civ. 4023, 2007 WL
950137, at *3 (S.D.N.Y. Mar. 29, 2007) (citation omitted). To succeed on an implied warranty
claim, Plaintiff must establish: “(1) that the product was defectively designed or manufactured;
(2) that the defect existed when the manufacturer delivered it to the purchaser or user; and (3)
that the defect is the proximate cause of the accident.” Id. at *3 (citations and internal quotations
omitted). One court has observed that “liability under strict products liability and implied
warranty theory are essentially the same.” Pinello, 2011 WL 1302223, at *17 (citation omitted);
see Lewis, 2009 WL 2231701, at *6 (“[P]laintiff has not pleaded necessary elements to support a
design, failure to warn, or manufacturing defect claim. Therefore, plaintiff has failed to plead an
essential element of her breach of implied warranty claim.”). Plaintiff has not adequately
9
pleaded facts in support of her allegation that the R3 Constrained Acetabular Liner was
defective. Therefore, this claim must be dismissed.
C.
Breach of Express Warranty
Any “affirmation of fact or promise made by the seller to the buyer which relates to the
goods and becomes part of the basis of the bargain creates an express warranty that the goods
shall conform to the affirmation or promise.” N.Y.U.C.C. § 2–313(1)(a). “To establish the
breach of an express warranty, the plaintiff must show that there was an ‘affirmation of fact or
promise by the seller, the natural tendency of which [was] to induce the buyer to purchase’ and
that the warranty was relied upon to the plaintiff’s detriment.” Barrett, 2008 WL 5170200, at
*12 (citations omitted) (alteration in original). In other words, “[a] successful claim of a breach
of express warranty requires proof that an express warranty existed, was breached, and that
plaintiff had relied on that warranty.” Reed, 839 F. Supp. 2d at 578 (citations omitted). “The
plaintiff must set forth the terms of the warranty upon which he relied.” Id. (citations omitted).
Where a “[p]laintiff does not identify the terms of the purported warranty he claims to have
relied on,” any “conclusory allegation . . . for breach of express warranty [must] be dismissed.”
Pinello, 2011 WL 1302223, at *17. Further, “a successful breach of warranty claim requires that
the product be defective.” Reed, 839 F. Supp. 2d at 578 (citing Plemmons, 2007 WL 950137, at
*5). Plaintiff has not alleged with sufficient specificity the requisite representation by Smith &
Nephew, nor has Plaintiff alleged sufficient facts in support of her allegation that the R3
Constrained Acetabular Liner was, in fact, defective. Accordingly, this claim must be dismissed.
D.
Negligence
“New York courts generally consider strict products liability and negligence claims to be
‘functionally synonymous.’” Pinello, 2011 WL 1302223, at *16 (quoting Penny v. Ford Motor
10
Co., 639 N.Y.S.2d 250 (1995)). “[A] negligence claim requires the plaintiff to show that (1) the
manufacturer owed plaintiff a duty to exercise reasonable care; (2) the manufacturer breached
that duty by failing to use reasonable care so that the product was rendered defective; (3) the
defect was the proximate cause of the plaintiff's injury; and (4) plaintiff suffered loss or
damage.” Lewis, 2009 WL 2231701, at *3 (quotation marks and citations omitted). Where a
plaintiff fails to plead “facts making it plausible (1) that anything that defendants did or failed to
do fell below the standard of reasonable care or (2) that the [disputed product] was defective in
any way including in its warnings, manufacture, or design,” she cannot state a negligence claim
under New York law. Reed, 839 F. Supp. 2d at 578 n.6 (citation omitted). Plaintiff alleges that
Smith & Nephew knew or should have known about the risks associated with the R3 Constrained
Acetabular Liner was defective, but does not offer factual allegations to support this legal
conclusion. Further, as explained above, Plaintiff has failed to allege sufficient facts in support
of her allegation that the R3 Constrained Acetabular Liner was, in fact, defective. This claim
must be dismissed.
E.
Consumer Protection Statute
Plaintiff’s final cause of action invokes New York General Business Law § 349. In this
cause of action, Plaintiff alleges that Smith & Nephew “failed to adequately warn consumers and
the medical community of the safety risks associated with the R3 Constrained Acetabular Liner”
and made “false and misleading representations and omissions of material facts regarding the
safety and potential risks of the R3 Constrained Acetabular Liner.” For the reasons stated above
with respect to Plaintiff’s other allegations, this claim must be dismissed.
11
F.
Leave to Amend
Plaintiff requests leave to address any pleading deficiencies in an amended complaint.
Rule 15(a) of the Federal Rules of Civil Procedure provides that leave to amend a pleading “shall
be freely given when justice so requires.” There has been no prior dismissal of the Complaint,
Plaintiff has not previously amended its pleadings, and Defendant has not demonstrated that it
would be prejudicial, futile, or otherwise unfair for Plaintiff to be afforded leave to amend.
Indeed, given that the Complaint was drafted as part of a state court filing, but is now subject to
the higher pleading standards applicable in federal court, it would be particularly consistent with
principles of fairness and justice to afford Plaintiff an opportunity to file an amended complaint.
Whether or not the Plaintiff can actually cure the deficiencies in the Complaint remains to be
seen, but because the Court bases its dismissal of the Complaint primarily on Plaintiff’s failure to
allege non-conclusory facts in support of its claims, leave to replead is appropriate. See Reed,
839 F. Supp. 2d at 580 (noting “the high value to be placed on merit resolution of cases”).
IV.
Conclusion
For the foregoing reasons, Defendants’ motion to dismiss is GRANTED without
prejudice. Plaintiff is granted to leave to file an amended complaint within the next 60 days.
The Clerk of Court is directed to close the motion at Dkt. No. 9.
SO ORDERED.
Dated: New York, New York
April 24, 2013
12
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?